Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

R^1 is selected from hydrogen, C_{1-6}alkyl, hydroxy, cyano, nitro, halo, C_{1-6}haloalkyl, XCO_2R^8, $-XC(O)NR^7R^8$, $-XNR^6C(O)R^7$, $-XNR^6C(O)NR^7R^8$, $-XNR^6C(O)NC(O)NR^7R^8$, $-XNR^6SO_2R^7$, $-XSO_2NR^9R^{10}$, XSR^6, $XSOR^6$, XSO_2R^6, $-XNR^7R^8$, $-XNR^6C(O)OR^7$,
or R^1 is selected from -X-aryl, -X-hetaryl, or -X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C_{1-6}alkoxy, halo, C_{1-6}alkyl,
C_{1-6}haloalkyl, $-NR^6C(O)R^7$, SR^6, SOR^6, $-SO_2R^6$, $-SO_2NR^9R^{10}$, $-CO_2R^8$, $-NR^7R^8$, or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C_{1-6}alkoxy, halo, C_{1-6}alkyl, or C_{1-6}haloalkyl;

X is $-(CH_2)_q-$ or C_{2-6} alkenylene;

q is an integer from 0 to 6~~, preferably 0 to 4~~;

R^6 and R^7 are independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, aryl, hetaryl, hetaryl(C_{1-6}alkyl)- and aryl(C_{1-6}alkyl)- and R^6 and R^7 are each

independently optionally substituted by 1 or 2 groups independently selected from halo, C_{1-6}alkyl,
C_{3-7} cycloalkyl, C_{1-6} alkoxy, C_{1-6}haloalkyl, -NHC(O)(C_{1-6}alkyl), -SO_2(C_{1-6}alkyl), -SO_2(aryl), -CO_2H, and -CO_2(C_{1-4}alkyl), -NH_2, -NH(C_{1-6}alkyl), aryl(C_{1-6}alkyl)-, aryl(C_{2-6}alkenyl)-,
aryl(C_{2-6}alkynyl)-, hetaryl(C_{1-6}alkyl)-, -$NHSO_2$aryl, -NH(hetarylC_{1-6}alkyl), -$NHSO_2$hetaryl,
-$NHSO_2$(C_{1-6}alkyl), -NHC(O)aryl, or -NHC(O)hetaryl:

R^8 is selected from hydrogen, C_{1-6}alkyl and C_{3-7} cycloalkyl;

or R^7 and R^8, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7- membered nitrogen – containing ring;

R^9 and R^{10} are independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, aryl, hetaryl, hetaryl(C_{1-6}alkyl)- and aryl(C_{1-6}alkyl)-, or R^9 and R^{10}, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7- membered nitrogen containing ring;
and R^9 and R^{10} are each optionally substituted by one or two groups independently selected from halo, C_{1-6}alkyl, and C_{3-7}cycloalkyl, C_{1-6}haloalkyl;

R^2 is selected from hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, halo, aryl, aryl(C_{1-6}alkyl)-, C_{1-6}haloalkoxy, and C_{1-6}haloalkyl;

R^3 is selected from hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, halo, aryl, aryl(C_{1-6}alkyl)-,
C_{1-6}haloalkoxy, and C_{1-6}haloalkyl; and

R^4 and R^5 are independently selected from hydrogen and C_{1-4} alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

R^a and R^b each independently represent hydrogen or C_{1-4}alkyl;

Ar^1 is a group selected from



(a)



(b)



(c)

and



(d)

wherein R^{11} represents hydrogen, halogen, $-(CH_2)_rOR^{15}$, $-NR^{15}C(O)R^{16}$, $-NR^{15}SO_2R^{16}$,
$-SO_2NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$,
and R^{12} represents hydrogen, halogen or C_{1-4} alkyl;

or R^{11} represents $-NHR^{18}$ and R^{12} and $-NHR^{18}$ together form a 5- or 6-membered heterocyclic ring;

R^{13} represents hydrogen, halogen, $-OR^{15}$ or $-NR^{15}R^{16}$;

R^{14} represents hydrogen, halogen, haloC_{1-4} alkyl, $-OR^{15}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$;

R^{15} and R^{16} each independently represents hydrogen or C_{1-4} alkyl, or in the groups

$-NR^{15}R^{16}$, $-SO_2NR^{15}R^{16}$ and $-OC(O)NR^{15}R^{16}$, R^{15} and R^{16} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{17} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

r is zero or an integer from 1 to 4;

Z is O, CH_2- or a single bond;

n is an integer of from 1 to 4;
m is zero or an integer of from 1 to 4;
p is zero or an integer of from 1 to 3;
k is an integer from 1 to 3; and
t is zero or 1.

2. (Original) A compound of formula (Ia):



(Ia)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

k is an integer from 1 to 3;
n is an integer of from 1 to 4;
m is an integer of from 2 to 4;
p is an integer of from 1 to 4;
Z is O or CH_2-;

R^1 is selected from hydrogen, C_{1-6}alkyl, hydroxy, cyano, nitro, halo, C_{1-6}haloalkyl, XCO_2R^8, $-XC(O)NR^7R^8$, $-XNR^6C(O)R^7$, $-XNR^6C(O)NR^7R^8$, $-XNR^6C(O)NC(O)NR^7R^8$, $-XNR^6SO_2R^7$, $-XSO_2NR^9R^{10}$, XSR^6, $XSOR^6$, XSO_2R^6, $-XNR^7R^8$, $-XNR^6C(O)OR^7$,
or R^1 is selected from -X-aryl, -X-hetaryl, or -X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C_{1-6}alkoxy, halo, C_{1-6}alkyl,
C_{1-6}haloalkyl, $-NR^6C(O)R^7$, SR^6, SOR^6, $-SO_2R^6$, $-SO_2NR^9R^{10}$, $-CO_2R^8$, $-NR^7R^8$, or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C_{1-6}alkoxy, halo, C_{1-6}alkyl, or C_{1-6}haloalkyl;

X is $-(CH_2)_q-$ or C_{2-6} alkenylene;

q is an integer from 0 to 6;

R^6 and R^7 are independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, aryl, hetaryl, hetaryl(C_{1-6}alkyl)- and aryl(C_{1-6}alkyl)- and R^6 and R^7 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C_{1-6}alkyl,
C_{3-7} cycloalkyl, C_{1-6} alkoxy, C_{1-6}haloalkyl, $-NHC(O)(C_{1-6}$alkyl), $-SO_2(C_{1-6}$alkyl), $-SO_2$(aryl), $-CO_2H$, and $-CO_2(C_{1-4}$alkyl), $-NH_2$, $-NH(C_{1-6}$alkyl), aryl(C_{1-6}alkyl)-, aryl(C_{2-6}alkenyl)-,
aryl(C_{2-6}alkynyl)-, hetaryl(C_{1-6}alkyl)-, $-NHSO_2$aryl, -NH(hetarylC_{1-6}alkyl), $-NHSO_2$hetaryl,
$-NHSO_2(C_{1-6}$alkyl), -NHC(O)aryl, or -NHC(O)hetaryl:

R^8 is selected from hydrogen, C_{1-6}alkyl and C_{3-7} cycloalkyl;

or R^7 and R^8, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7- membered nitrogen – containing ring;

R^9 and R^{10} are independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, aryl, hetaryl, hetaryl(C_{1-6}alkyl)- and aryl(C_{1-6}alkyl)-, or R^9 and R^{10}, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7- membered nitrogen containing ring;
and R^9 and R^{10} are each optionally substituted by one or two groups independently selected from halo, C_{1-6}alkyl, and C_{3-7}cycloalkyl, C_{1-6}haloalkyl;

R^2 is selected from hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, halo, aryl, aryl(C_{1-6}alkyl)-, C_{1-6}haloalkoxy, and C_{1-6}haloalkyl;

R^3 is selected from hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, halo, aryl, aryl(C_{1-6}alkyl)-,
C_{1-6}haloalkoxy, and C_{1-6}haloalkyl; and

R^4 and R^5 are independently selected from hydrogen and C_{1-4} alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

Ar^1 is a group selected from



(a)



(b)



(c)

and



(d)

wherein R^{11} represents halogen, $-(CH_2)_rOR^{15}$, $-NR^{15}C(O)R^{16}$, $-NR^{15}SO_2R^{16}$, $-SO_2NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$,
and R^{12} represents hydrogen, halogen or C_{1-4} alkyl;

or R^{11} represents $-NHR^{18}$ and R^{12} and $-NHR^{18}$ together form a 5- or 6-membered heterocyclic ring;

R^{13} represents hydrogen, halogen, $-OR^{15}$ or $-NR^{15}R^{16}$;

R^{14} represents hydrogen, halogen, haloC_{1-4} alkyl, $-OR^{15}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$

R^{15} and R^{16} each independently represents hydrogen or C_{1-4} alkyl, or in the groups
$-NR^{15}R^{16}$, $-SO_2NR^{15}R^{16}$ and $-OC(O)NR^{15}R^{16}$, R^{15} and R^{16} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{17} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

r is zero or an integer from 1 to 4.

3. (Currently Amended) A compound according to claim 1 ~~or claim 2~~ wherein the group R^1 is selected from hydrogen, C_{1-4}alkyl, hydroxy, halo, $-NR^6C(O)NR^7R^8$, $-NR^6C(O)R^7$, $-SO_2NR^9R^{10}$, $-SOR^6$, $-SO_2R^6$, and $-NR^6SO_2R^7$ wherein R^6 and R^7 are as defined in claim 1 or claim 2.

4. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 3~~ wherein R^2 and R^3 are independently selected from hydrogen, hydroxyl, halogen, haloC_{1-6}alkyl, C_{1-6}alkyl, C_{1-6}alkoxy and haloC_{1-6}alkoxy.

5. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 4~~ wherein R^4 and R^5 each represent hydrogen.

6. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 5~~ wherein R^a and R^b each represent hydrogen.

7. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 6~~ wherein the group Ar^1 is selected from groups (a) and (b) ~~as defined in claim 1~~.

8. (Original) A compound according to claim 7 wherein the group (a) is a group of formula (i):



(i)

9. (Currently Amended) A compound according to claim 1 selected from the group consisting of :

4-((1*R*)-2-{[2-(3-{[2-(Benzyloxy)ethoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-{(1*R*)-2-[(2-{3-[(Benzyloxy)methyl]phenyl}ethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;

2-(Hydroxymethyl)-4-{(1*R*)-1-hydroxy-2-[(2-{3-[(3-phenylpropoxy)methyl]phenyl}ethyl)amino]ethyl}phenol;

2-(Hydroxymethyl)-4-{(1*R*)-1-hydroxy-2-[(2-{3-[(4-phenylbutoxy)methyl]phenyl}ethyl)amino]ethyl}phenol;

4-((1*R*)-2-{[2-(3-{[3-(Benzyloxy)propoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-{[2-(4-{[2-(Benzyloxy)ethoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

2-(Hydroxymethyl)-4-{(1*R*)-1-hydroxy-2-[(2-{3-[(2-phenylethoxy)methyl]phenyl}ethyl)amino]ethyl}phenol;

4-((1*R*)-2-{[2-(3-{[(2,6-Dichlorobenzyl)oxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-1-Hydroxy-2-{[2-(3-{[2-(2-methoxyphenyl)ethoxy]methyl}phenyl)ethyl]amino}ethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-1-Hydroxy-2-{[2-(3-{[2-(3-methoxyphenyl)ethoxy]methyl}phenyl)ethyl]amino}ethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-1-Hydroxy-2-{[2-(3-{[2-(4-methoxyphenyl)ethoxy]methyl}phenyl)ethyl]amino}ethyl)-2-(hydroxymethyl)phenol;

3-[4-({3-[2-({(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)butyl]benzenesulfonamide;

3-{[2-({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)ethoxy]methyl}benzonitrile;

4-[(1R)-2-({2-[3-({2-[(2,6-dichlorobenzyl)oxy]ethoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

4-[(1R)-2-({2-[3-({2-[(3-fluorobenzyl)oxy]ethoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
4-[(1R)-2-({2-[3-({2-[(3,5-dimethylbenzyl)oxy]ethoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
4-[(1R)-1-hydroxy-2-({2-[3-({2-[(3-methoxybenzyl)oxy]ethoxy}methyl)phenyl]ethyl}amino)ethyl]-2-(hydroxymethyl)phenol;
2-(hydroxymethyl)-4-{(1R)-1-hydroxy-2-[(2-{3-[(2-{[3-(trifluoromethoxy)benzyl]oxy}ethoxy)methyl]phenyl}ethyl)amino]ethyl}phenol;
4-((1R)-1-hydroxy-2-{[2-(3-{[4-(3-hydroxyphenyl)butoxy]methyl}phenyl)ethyl]amino}ethyl)-2-(hydroxymethyl)phenol;
4-[3-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)propyl]benzonitrile;
4-[4-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)butyl]benzonitrile;
3-[3-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)propyl]benzonitrile;
2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-({2-[3-({3-[4-(methylsulfonyl)phenyl]propoxy}methyl)phenyl]ethyl}amino)ethyl]phenol;
2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-({2-[3-({[4-(methylsulfonyl)benzyl]oxy}methyl)phenyl]ethyl}amino)ethyl]phenol;
4-((1R)-1-hydroxy-2-{[2-(3-{[2-(2-hydroxyphenyl)ethoxy]methyl}phenyl)ethyl]amino}ethyl)-2-(hydroxymethyl)phenol;
4-((1R)-1-hydroxy-2-{[2-(3-{[(4-hydroxybenzyl)oxy]methyl}phenyl)ethyl]amino}ethyl)-2-(hydroxymethyl)phenol;
4-((1R)-1-hydroxy-2-{[2-(3-{[3-(3-hydroxyphenyl)propoxy]methyl}phenyl)ethyl]amino}ethyl)-2-(hydroxymethyl)phenol;

4-[(1*R*)-2-({2-[3-({4-[4-(cyclopentylsulfonyl)phenyl]butoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
4-[(1*R*)-2-({2-[3-({3-[4-(cyclopentylsulfonyl)phenyl]propoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
4-[(1*R*)-2-({2-[3-({3-[3-(cyclopentylsulfonyl)phenyl]propoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
4-[(1R)-1-hydroxy-2-({2-[3-({2-[(3-hydroxybenzyl)oxy]ethoxy}methyl)phenyl]ethyl}amino)ethyl]-2-(hydroxymethyl)phenol;
4-{(1R)-2-[(2-{3-[(2-{[3-(cyclopentylsulfonyl)benzyl]oxy}ethoxy)methyl]phenyl}ethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-{(1R)-2-[(2-{3-[(2-{[3-(cyclopentylsulfinyl)benzyl]oxy}ethoxy)methyl]phenyl}ethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-[(1*R*)-2-({2-[3-({[3-(cyclopentylsulfonyl)benzyl]oxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
4-[(1R)-2-({2-[3-({4-[3-(cyclopentylsulfinyl)phenyl]butoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
3-[4-({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)butyl]benzonitrile;
2-(hydroxymethyl)-4-{(1R)-1-hydroxy-2-[(2-{3-[(2-phenoxyethoxy)methyl]phenyl}ethyl)amino]ethyl}phenol;
4-((1R)-2-{[2-(3-{[2-(3-fluorophenyl)ethoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1R)-2-{[2-(3-{[2-(4-fluorophenyl)ethoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1R)-2-{[2-(3-{[2-(2-fluorophenyl)ethoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
3-[({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)methyl]benzonitrile;
4-[({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)methyl]benzonitrile;
2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-({2-[3-({[(1R)-1-phenylethyl]oxy}methyl)phenyl]ethyl}amino)ethyl]phenol;
2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-({2-[3-({[(1S)-1-phenylethyl]oxy}methyl)phenyl]ethyl}amino)ethyl]phenol;
4-((1R)-2-{[2-(3-{[(3,5-dimethylbenzyl)oxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1R)-2-{[2-(3-{[(2,6-dichlorobenzyl)oxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1R)-2-{[2-(3-{[(2-fluorobenzyl)oxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1R)-2-{[2-(3-{[(3-fluorobenzyl)oxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1R)-2-{[2-(3-{[(4-fluorobenzyl)oxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
3-[4-({3-[2-({(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)butyl]benzamide;
3-{[2-({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)ethoxy]methyl}benzamide;
3-[({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)methyl]benzamide;
4-[({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)methyl]benzamide;
3-[2-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)ethyl]benzenesulfonamide;
3-[3-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)propyl]benzenesulfonamide;

4-((1*R*)-2-{[2-(3-{[4-(2,6-dichlorophenyl)butoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
N-{3-[4-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)butyl]phenyl}urea;
2-(hydroxymethyl)-4-((1*R*)-1-hydroxy-2-{[2-(3-{[2-(1-phenylethoxy)ethoxy]methyl}phenyl)ethyl]amino}ethyl)phenol;
4-[(1*R*)-2-({2-[3-({2-[3-(cyclopentylsulfonyl)phenyl]ethoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
4-[(1*R*)-2-({2-[3-({4-[3-(cyclopentylsulfonyl)phenyl]butoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
2-(hydroxymethyl)-4-[(1*R*)-1-hydroxy-2-({2-[3-({4-[3-(methylsulfonyl)phenyl]butoxy}methyl)phenyl]ethyl}amino)ethyl]phenol;
4-((1*R*)-2-{[2-(3-{[3-(2,6-dichlorophenyl)propoxy]methyl}phenyl)ethyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
3-[({3-[2-({(2*R*)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)methyl]benzenesulfonamide, salts thereof, solvates thereof, and physiologically functional derivatives thereof

~~or a salt, solvate or physiologically functional derivative thereof~~.

10. (Currently Amended) A method for the prophylaxis or treatment of a clinical condition in a mammal~~, such as a human,~~ for which a selective β_2-adrenoreceptor agonist is indicated, which comprises ~~administration of~~ administering a therapeutically effective amount of a compound of formula (I) according to claim 1 ~~any of claims 1 to 9~~, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

11-12. (Cancelled)

13. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I), according to claim 1 ~~any of claims 1 to 9~~, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

14. (Cancelled)

15. (Currently Amended) A process for the preparation of a compound of formula (I), according to claim 1 ~~any of claims 1 to 9~~, or a salt, solvate, or physiologically functional derivative thereof, which comprises~~:~~

~~(a)~~ ~~deprotection of~~ deprotecting a protected intermediate~~, for example~~ of formula (II):



(II)

or a salt or solvate thereof, wherein R^1, R^2, R^3, R^4, R^5, Z, k, m, n and p are as defined for the compound of formula (I), and P^1 and P^2 each independently represents hydrogen or a protecting group provided that the compound of formula (II) contains at least one protecting group~~; or~~

~~(b) alkylation of an amine of formula (X)~~



(X)

~~wherein Ar^{1a} is as hereinbefore defined, P^2 and P^1 are each independently either hydrogen or a protecting group,~~

~~with a compound of formula (XI):~~



(XI)

~~wherein R^1, R^2, R^3, R^4, R^5, Z, k, m, n and p are as defined for the compound of formula (I) and L^1 is a leaving group;~~

~~(c) reacting a compound of formula (XII):~~



(XII)

~~wherein Ar^1 and P^1 are as hereinbefore defined and L^1 is a leaving group, with an amine of formula (XIII):~~



(XIII)

~~or~~

~~d) reacting a compound of formula (X):~~



(X)

~~as hereinbefore defined,~~

~~with a compound of formula (XIV):~~



(XIV)

~~under conditions suitable to effect reductive amination;~~

wherein said deprotecting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) ~~optional removal of~~ removing any protecting groups;

(ii) ~~optional separation of~~ separating an enantiomer from a mixture of enantiomers; and

(iii) ~~optional conversion of~~ converting the product to a corresponding salt, solvate,

or physiologically functional derivative thereof.

16. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises

alkylating an amine of formula (X)



(X)

wherein Ar^{1a} is Ar^1 or a protected form thereof, and P^2 and P^1 are each independently either hydrogen or a protecting group,

with a compound of formula (XI):



(XI)

wherein R^1, R^2, R^3, R^4, R^5, Z, k, m, n and p are as defined for the compound of formula (I) and L^1 is a leaving group;

wherein said alkylating step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers; and

(iii) converting the product to a corresponding salt, solvate,

or physiologically functional derivative thereof.

17. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises

reacting a compound of formula (XII):



(XII)

wherein Ar^{1a} is Ar^1 or a protected form thereof, P^1 is either hydrogen or a protecting group and L^1 is a leaving group, with an amine of formula (XIII):



(XIII)

wherein P^2 is either hydrogen or a protecting group

wherein said reacting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers; and

(iii) converting the product to a corresponding salt, solvate,

or physiologically functional derivative thereof.

18. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises

reacting a compound of formula (X):



(X)

wherein Ar^{1a} is Ar^1 or a protected form thereof, and P^1 and P^2 are each independently either hydrogen or a protecting group,

with a compound of formula (XIV):



(XIV)

under conditions suitable to effect reductive amination;

wherein said reacting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers; and

(iii) converting the product to a corresponding salt, solvate,

or physiologically functional derivative thereof.

19. (New) The method according to Claim 10, wherein the mammal is a human.

20. (New) The method according to Claim 10, wherein the clinical condition is asthma.

21. (New) The method according to Claim 10, wherein the clinical condition is COPD.